PL2763654T3 - Kompozycje oftalmiczne zawierające pochodne prostaglandyny f2 alfa i kwas hialuronowy - Google Patents
Kompozycje oftalmiczne zawierające pochodne prostaglandyny f2 alfa i kwas hialuronowyInfo
- Publication number
- PL2763654T3 PL2763654T3 PL12759652T PL12759652T PL2763654T3 PL 2763654 T3 PL2763654 T3 PL 2763654T3 PL 12759652 T PL12759652 T PL 12759652T PL 12759652 T PL12759652 T PL 12759652T PL 2763654 T3 PL2763654 T3 PL 2763654T3
- Authority
- PL
- Poland
- Prior art keywords
- ophthtalmic
- prostaglandin
- compositions
- hyaluronic acid
- alpha derivatives
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title 1
- 229920002674 hyaluronan Polymers 0.000 title 1
- 229960003160 hyaluronic acid Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306137A EP2567689A1 (en) | 2011-09-12 | 2011-09-12 | Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid |
| EP12759652.6A EP2763654B1 (en) | 2011-09-12 | 2012-09-11 | Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid |
| PCT/EP2012/003810 WO2013037479A1 (en) | 2011-09-12 | 2012-09-11 | Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2763654T3 true PL2763654T3 (pl) | 2020-11-02 |
Family
ID=46875737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12759652T PL2763654T3 (pl) | 2011-09-12 | 2012-09-11 | Kompozycje oftalmiczne zawierające pochodne prostaglandyny f2 alfa i kwas hialuronowy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140228364A1 (pl) |
| EP (2) | EP2567689A1 (pl) |
| JP (1) | JP2014528930A (pl) |
| CN (1) | CN103957887B (pl) |
| AU (1) | AU2012307812A1 (pl) |
| BR (1) | BR112014005700A2 (pl) |
| CA (1) | CA2848156A1 (pl) |
| ES (1) | ES2792061T3 (pl) |
| IL (1) | IL231264A0 (pl) |
| MX (1) | MX2014002918A (pl) |
| PL (1) | PL2763654T3 (pl) |
| WO (1) | WO2013037479A1 (pl) |
| ZA (1) | ZA201401787B (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| CN104288092A (zh) * | 2013-07-16 | 2015-01-21 | 广东东阳光药业有限公司 | 拉坦前列素滴眼剂 |
| US9115109B2 (en) | 2013-08-15 | 2015-08-25 | Chirogate International Inc. | Processes and intermediates for the preparations of isomer free prostaglandins |
| GR1008483B (el) * | 2013-12-23 | 2015-05-12 | Rafarm Α.Ε.Β.Ε., | Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης |
| WO2016013993A1 (en) * | 2014-07-25 | 2016-01-28 | Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. | Stable preservative free ophthalmic formulations of opioid antagonists |
| CN112022856A (zh) * | 2014-10-15 | 2020-12-04 | 爱尔康公司 | 用于治疗青光眼和眼压过高的前列腺素偶联物和衍生物 |
| PL3250212T3 (pl) * | 2015-01-27 | 2020-06-15 | Apharm S.R.L. | Kombinacja kwasu hialuronowego i makrogolu oraz zawierające ją kompozycje farmaceutyczne |
| RU2576778C1 (ru) * | 2015-02-20 | 2016-03-10 | Илья Александрович Марков | Фармацевтическая композиция в виде гелеобразных глазных капель для лечения глаукомы |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| GR1009006B (el) * | 2016-04-01 | 2017-04-04 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη |
| GR1009040B (el) * | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
| KR101770324B1 (ko) * | 2016-11-09 | 2017-08-22 | 주식회사태준제약 | 안압 강하용 점안 조성물 |
| CA3097470A1 (en) * | 2018-04-18 | 2019-10-24 | i.com medical GmbH | High molecular weight hyaluronic acid for enhancing epithelial survival and reconstitution of body surfaces |
| WO2019202017A1 (en) | 2018-04-18 | 2019-10-24 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| CN109172580B (zh) * | 2018-09-06 | 2021-04-27 | 中山万汉制药有限公司 | 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂 |
| WO2020157570A1 (en) | 2019-01-31 | 2020-08-06 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
| CN110711175A (zh) * | 2019-11-12 | 2020-01-21 | 南京华盖制药有限公司 | 一种他氟前列素滴眼剂及其制备方法 |
| CA3167756A1 (en) * | 2020-02-04 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors |
| JP7828519B2 (ja) * | 2020-06-21 | 2026-03-12 | アイ．コム メディカル ゲーエムベーハー | 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用 |
| JP6855026B1 (ja) * | 2020-11-09 | 2021-04-07 | 東亜薬品株式会社 | タフルプロスト点眼液 |
| CN115322095A (zh) * | 2021-01-27 | 2022-11-11 | Ａｇｃ株式会社 | 他氟前列素的纯化方法 |
| CN114295741B (zh) * | 2021-12-17 | 2025-01-10 | 沈阳兴齐眼药股份有限公司 | 对包含在溶液样品中的曲伏前列素和曲伏前列素酸同时进行定量分析的方法 |
| CN116687842A (zh) * | 2022-02-28 | 2023-09-05 | 山东新时代药业有限公司 | 一种拉坦前列素滴眼液及其制备方法 |
| CN114796219B (zh) * | 2022-05-18 | 2024-08-20 | 沈阳药科大学 | 一种用于治疗青光眼的复方药物组合物及其用途 |
| US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
| EP4616843A1 (en) * | 2024-03-13 | 2025-09-17 | Iakov Mirkin | Pharmaceutical composition for use in the treatment of ulcerative colitis and in the treatment of interstitial cystitis/bladder pain syndrome |
| CN120661442A (zh) * | 2025-08-12 | 2025-09-19 | 济民健康管理股份有限公司 | 一种滴眼液的组合物及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409125A (en) | 1989-12-11 | 1995-04-25 | Aktiebolaget Astra | Unit dose container |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| CA2273837C (en) | 1996-12-09 | 2003-12-30 | Bausch & Lomb Incorporated | Single-use flexible container |
| AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| CA2295512C (en) | 1998-07-14 | 2009-05-26 | Alcon Laboratories, Inc. | Prostaglandin product |
| EP1321144B1 (en) | 2000-09-13 | 2010-12-08 | Santen Pharmaceutical Co., Ltd. | Eye drops |
| CN1488404A (zh) * | 2003-06-19 | 2004-04-14 | 刘继东 | 眼用制剂中玻璃酸钠的复合应用 |
| EP1642584A1 (en) * | 2003-06-25 | 2006-04-05 | Cardiovascular Institute, Ltd | External preparation for improving coital function |
| US20060199863A1 (en) | 2003-07-31 | 2006-09-07 | Santen Pharmaceutical Co., Ltd. | Product containing prostaglandin |
| DK1759702T3 (da) * | 2004-05-26 | 2009-04-20 | Bayardo Arturo Jimenez | Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning |
| JP2006176457A (ja) * | 2004-12-24 | 2006-07-06 | Wakamoto Pharmaceut Co Ltd | 医薬用水性液状組成物 |
| US7306129B2 (en) * | 2005-11-03 | 2007-12-11 | Stewart Swiss | One way valve assembly |
| DE602006016628D1 (de) | 2005-10-10 | 2010-10-14 | Novagali Pharma Sa | Prostaglandine enthaltende ophthalmische emulsionen |
| TW200733993A (en) * | 2005-11-03 | 2007-09-16 | Reseal Internat Ltd Partnership | Continuously sealing one way valve assembly and fluid delivery system and formulations for use therein |
| KR100845942B1 (ko) * | 2006-07-10 | 2008-07-11 | 주식회사태준제약 | 부작용이 경감된 점안용 조성물과 그의 제조 방법 |
| EP2178501B1 (en) * | 2007-07-26 | 2018-05-02 | Azad Pharma AG | Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions |
| ITRM20080182A1 (it) * | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
| US20100104654A1 (en) * | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| DE102009021372A1 (de) * | 2009-05-14 | 2010-11-18 | Ursapharm Arzneimittel Gmbh | Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung |
| EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
-
2011
- 2011-09-12 EP EP11306137A patent/EP2567689A1/en not_active Withdrawn
-
2012
- 2012-09-11 JP JP2014528900A patent/JP2014528930A/ja active Pending
- 2012-09-11 AU AU2012307812A patent/AU2012307812A1/en not_active Abandoned
- 2012-09-11 US US14/342,779 patent/US20140228364A1/en not_active Abandoned
- 2012-09-11 CA CA2848156A patent/CA2848156A1/en not_active Abandoned
- 2012-09-11 WO PCT/EP2012/003810 patent/WO2013037479A1/en not_active Ceased
- 2012-09-11 EP EP12759652.6A patent/EP2763654B1/en active Active
- 2012-09-11 CN CN201280050592.7A patent/CN103957887B/zh active Active
- 2012-09-11 MX MX2014002918A patent/MX2014002918A/es not_active Application Discontinuation
- 2012-09-11 BR BR112014005700A patent/BR112014005700A2/pt not_active IP Right Cessation
- 2012-09-11 PL PL12759652T patent/PL2763654T3/pl unknown
- 2012-09-11 ES ES12759652T patent/ES2792061T3/es active Active
-
2014
- 2014-03-02 IL IL231264A patent/IL231264A0/en unknown
- 2014-03-11 ZA ZA2014/01787A patent/ZA201401787B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2792061T3 (es) | 2020-11-06 |
| EP2567689A1 (en) | 2013-03-13 |
| AU2012307812A1 (en) | 2014-04-17 |
| EP2763654A1 (en) | 2014-08-13 |
| CN103957887A (zh) | 2014-07-30 |
| CN103957887B (zh) | 2018-02-06 |
| BR112014005700A2 (pt) | 2017-03-28 |
| JP2014528930A (ja) | 2014-10-30 |
| MX2014002918A (es) | 2014-11-21 |
| AU2012307812A8 (en) | 2015-06-11 |
| IL231264A0 (en) | 2014-04-30 |
| EP2763654B1 (en) | 2020-04-29 |
| WO2013037479A8 (en) | 2014-05-30 |
| WO2013037479A1 (en) | 2013-03-21 |
| US20140228364A1 (en) | 2014-08-14 |
| CA2848156A1 (en) | 2013-03-21 |
| ZA201401787B (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201401787B (en) | Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid | |
| PL2637710T3 (pl) | Preparaty na bazie kwasu hialuronowego | |
| ZA201308086B (en) | Derivatives of 1-anino-2-cyclopropylboronic acid | |
| IL231227A0 (en) | Compounds and preparations as kit inhibitors - c | |
| IL231226A0 (en) | Compounds and preparations as kit inhibitors - c | |
| EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| GB201113662D0 (en) | Pharmaceutical compositions | |
| IL223153A0 (en) | Compositions comprising acid and derivatives thereof and uses thereof | |
| PL2793822T3 (pl) | Kompozycje wytwarzające kwas nadtlenowy | |
| AP3656A (en) | Pharmaceutical compositions | |
| EP2680848A4 (en) | STABLE TETRAHYDROBIOPTERINE COMPOSITIONS | |
| GB201113770D0 (en) | Novel compositions and uses thereof | |
| EP2825057B8 (en) | Oxidixable fatty acid composition delivery form | |
| EP2661179A4 (en) | COMPOSITION WITH REDUCED SODIUM CONTENT | |
| PT2768864T (pt) | Composições com concentrações aumentadas de carboximetilcelulose | |
| PT2598109T (pt) | Composição para utilização tópica sem conservante compreendendo ácido hialurónico | |
| EP2665784B8 (de) | Verwendung von polyhydroxyalkanoaten als additive in beschichtungszusammensetzungen | |
| EP2768481A4 (en) | COMPOSITIONS TO REDUCE SIDE EFFECTS | |
| EP2867199A4 (en) | STABLE COMPOSITIONS OF ESOTRERODINE | |
| GB201118181D0 (en) | Pharmaceutical compositions | |
| ZA201402165B (en) | Compositions of lopinavir | |
| IL229696A0 (en) | Gel preparations | |
| EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
| AU2011900801A0 (en) | Novel compositions of dexemedetomidine | |
| GB201105224D0 (en) | Novel pharmaceutical compositions |